Innovations in brain cancer treatment continue to advance, fueled by the dedication of leading clinicians and researchers across the globe. In the latest episode of the Game On Glio podcast, Toral Patel, MD (UT Southwestern Medical Center) and Andrew Brenner, MD, PhD (UT Health San Antonio) joined host Shannon Traphagen for an in-depth conversation exploring the future of glioblastoma (GBM) therapy and the next wave of clinical research shaping patient care.
Listen to the full episode: https://lnkd.in/gsvtZJyw
Advancing the Conversation Around Glioblastoma Treatment
Glioblastoma remains one of the most aggressive and treatment-resistant brain cancers, with urgent need for new, more targeted therapeutic options. During their discussion, Dr. Patel and Dr. Brenner highlight:
-
Current challenges in treating recurrent GBM
-
The role of precision-guided therapies and localized delivery
-
How clinical research is reshaping the landscape of CNS oncology
-
The importance of multidisciplinary collaboration across major academic centers
Their insights underscore how innovation and clinical trial participation remain essential to accelerating progress for GBM patients worldwide.
About Plus Therapeutics’ ReSPECT-GBM Clinical Trial
As part of this broader effort to improve outcomes for patients with recurrent glioblastoma, Plus Therapeutics is conducting the ReSPECT-GBM Phase 2 clinical trial. This study is evaluating an investigational radiotherapeutic designed to deliver targeted beta radiation directly to the tumor site, with the goal of improving disease control while minimizing exposure to surrounding healthy tissue.
The trial is actively recruiting patients with malignant glioma who have experienced tumor recurrence following standard treatments such as surgery, radiation, or chemotherapy.
Learn more or see if you or someone you know may be eligible:
https://lnkd.in/dP9Gun6C
Moving Toward a New Era in Brain Cancer Treatment
Conversations like this one on Game On Glio help bring greater awareness to the scientific advancements under way in neuro-oncology. Through collaboration among leading institutions such as UT Health San Antonio and UT Southwestern Medical Center, researchers and clinicians are pushing the boundaries of what’s possible for patients facing glioblastoma.
Plus Therapeutics remains committed to developing innovative radiotherapeutic technologies that address significant unmet needs in brain cancer and other CNS malignancies.
Recent Comments